EP3185876A4 - Compositions and methods for treatment of neurological disorders - Google Patents

Compositions and methods for treatment of neurological disorders Download PDF

Info

Publication number
EP3185876A4
EP3185876A4 EP15835807.7A EP15835807A EP3185876A4 EP 3185876 A4 EP3185876 A4 EP 3185876A4 EP 15835807 A EP15835807 A EP 15835807A EP 3185876 A4 EP3185876 A4 EP 3185876A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
neurological disorders
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15835807.7A
Other languages
German (de)
French (fr)
Other versions
EP3185876B1 (en
EP3185876A1 (en
Inventor
Lilit GARIBYAN
Richard Rox Anderson
William A. Farinelli
Emilia JAVORSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to EP22189301.9A priority Critical patent/EP4176885A1/en
Publication of EP3185876A1 publication Critical patent/EP3185876A1/en
Publication of EP3185876A4 publication Critical patent/EP3185876A4/en
Application granted granted Critical
Publication of EP3185876B1 publication Critical patent/EP3185876B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
EP15835807.7A 2014-08-28 2015-08-27 Compositions and methods for treatment of neurological disorders Active EP3185876B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22189301.9A EP4176885A1 (en) 2014-08-28 2015-08-27 Compositions and methods for treatment of neurological disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462042979P 2014-08-28 2014-08-28
US201562121329P 2015-02-26 2015-02-26
US201562121472P 2015-02-26 2015-02-26
PCT/US2015/047292 WO2016033380A1 (en) 2014-08-28 2015-08-27 Compositions and methods for treatment of neurological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22189301.9A Division EP4176885A1 (en) 2014-08-28 2015-08-27 Compositions and methods for treatment of neurological disorders

Publications (3)

Publication Number Publication Date
EP3185876A1 EP3185876A1 (en) 2017-07-05
EP3185876A4 true EP3185876A4 (en) 2018-04-18
EP3185876B1 EP3185876B1 (en) 2022-08-10

Family

ID=55400611

Family Applications (4)

Application Number Title Priority Date Filing Date
EP15836780.5A Active EP3185854B1 (en) 2014-08-28 2015-08-27 Injectable slurries and methods of manufacturing and using the same
EP21200731.4A Withdrawn EP3988105A1 (en) 2014-08-28 2015-08-27 Injectable slurries and methods of manufacturing and using the same
EP15835807.7A Active EP3185876B1 (en) 2014-08-28 2015-08-27 Compositions and methods for treatment of neurological disorders
EP22189301.9A Pending EP4176885A1 (en) 2014-08-28 2015-08-27 Compositions and methods for treatment of neurological disorders

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP15836780.5A Active EP3185854B1 (en) 2014-08-28 2015-08-27 Injectable slurries and methods of manufacturing and using the same
EP21200731.4A Withdrawn EP3988105A1 (en) 2014-08-28 2015-08-27 Injectable slurries and methods of manufacturing and using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22189301.9A Pending EP4176885A1 (en) 2014-08-28 2015-08-27 Compositions and methods for treatment of neurological disorders

Country Status (16)

Country Link
US (5) US20170274078A1 (en)
EP (4) EP3185854B1 (en)
JP (6) JP6707525B2 (en)
KR (2) KR102507789B1 (en)
CN (4) CN117064838A (en)
AU (4) AU2015308790B2 (en)
BR (2) BR112017003143B1 (en)
CA (2) CA2958768C (en)
DK (2) DK3185854T3 (en)
ES (1) ES2898097T3 (en)
MX (3) MX2017002274A (en)
PL (1) PL3185854T3 (en)
PT (1) PT3185854T (en)
SG (4) SG10201913572TA (en)
WO (2) WO2016033380A1 (en)
ZA (3) ZA201701048B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9980765B2 (en) 2010-02-15 2018-05-29 The General Hospital Corporation Methods and devices for selective disruption of visceral fat by controlled cooling
JP5981932B2 (en) 2010-11-16 2016-08-31 ティーブイエー メディカル， インコーポレイテッド Devices and methods for forming folds
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
AU2013328944B2 (en) 2012-10-11 2018-05-24 Tva Medical, Inc. Devices and methods for fistula formation
EP2914186B1 (en) 2012-11-05 2019-03-13 Relievant Medsystems, Inc. Systems for creating curved paths through bone and modulating nerves within the bone
CA2905591C (en) 2013-03-14 2023-02-28 Tva Medical, Inc. Fistula formulation devices and methods therefor
WO2017123981A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
EA201691073A1 (en) 2013-12-05 2016-12-30 РФЕМБ ХОЛДИНГС, ЭлЭлСи CANCER IMMUNOTHERAPY USING RADIO-FREQUENCY ELECTRICAL BREAKDOWN MEMBRANE (RF-EMB)
US10695534B2 (en) 2014-03-14 2020-06-30 Tva Medical, Inc. Fistula formation devices and methods therefor
US10646666B2 (en) 2014-08-27 2020-05-12 Tva Medical, Inc. Cryolipolysis devices and methods therefor
WO2016033380A1 (en) 2014-08-28 2016-03-03 The General Hospital Corporation Compositions and methods for treatment of neurological disorders
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
WO2016053741A1 (en) 2014-10-01 2016-04-07 Cryosa, Llc Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
US10603040B1 (en) 2015-02-09 2020-03-31 Tva Medical, Inc. Methods for treating hypertension and reducing blood pressure with formation of fistula
US11161156B2 (en) * 2015-10-27 2021-11-02 Hamilton Sundstrand Corporation Powder monitoring
US10874422B2 (en) 2016-01-15 2020-12-29 Tva Medical, Inc. Systems and methods for increasing blood flow
EP4218642A3 (en) 2016-01-15 2023-08-09 TVA Medical, Inc. Devices and methods for forming a fistula
WO2017124059A1 (en) 2016-01-15 2017-07-20 Tva Medical, Inc. Devices and methods for advancing a wire
CN114576893A (en) 2016-02-26 2022-06-03 通用医疗公司 Medical ice slurry production and delivery system and method
MX2019003251A (en) 2016-09-25 2019-07-18 Tva Medical Inc Vascular stent devices and methods.
KR20200020657A (en) 2016-11-02 2020-02-26 크리스토퍼 제이 피 벨리스 Devices and Methods for Slurry Generation
US11324673B2 (en) * 2016-11-18 2022-05-10 Miraki Innovation Think Tank Llc Cosmetic appearance of skin
CA3065606A1 (en) * 2017-03-01 2018-09-07 Miraki Innovation Think Tank Llc Cryotherapies
US11439532B2 (en) * 2017-04-05 2022-09-13 Miraki Innovation Think Tank Llc Point of delivery cold slurry generation
BR112019020969A8 (en) 2017-04-05 2022-11-16 Miraki Innovation Think Tank Llc COLD FLUID PASTE CONTAINMENT
US10500342B2 (en) 2017-08-21 2019-12-10 Miraki Innovation Think Tank Llc Cold slurry syringe
WO2019113635A1 (en) * 2017-12-11 2019-06-20 Saban Ventures Pty Limited Suspension cleaning
KR20210073541A (en) * 2018-10-04 2021-06-18 미라키 이노베이션 씽크 탱크 엘엘씨 How to treat the subcutaneous fat layer
JP2022513342A (en) * 2018-10-04 2022-02-07 ミラキ イノベーション シンク タンク エルエルシー Slurry and solution composition
WO2020077090A1 (en) * 2018-10-10 2020-04-16 Miraki Innovation Think Tank Llc Systems and methods of generating slurry for injection
WO2020077089A1 (en) * 2018-10-10 2020-04-16 Miraki Innovation Think Tank Llc Systems and methods for generating slurry
SG11202103636TA (en) * 2018-10-12 2021-05-28 Miraki Innovation Think Tank Llc Cold solution for fat reduction
CN109800472B (en) * 2018-12-26 2022-09-27 哈尔滨工程大学 Blade surface instantaneous ice load pressure distribution calculation method in ice blade contact process
US11576812B2 (en) 2019-04-25 2023-02-14 Carlos Wambier Methods for reducing body fat in a subject
US20220273569A1 (en) 2019-07-24 2022-09-01 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
EP4027912A4 (en) 2019-09-12 2023-08-16 Relievant Medsystems, Inc. Systems and methods for tissue modulation
JP2022549499A (en) 2019-09-26 2022-11-25 ミラキ イノベーション シンク タンク エルエルシー Small, in-body controllable medical device
BR112022012482A2 (en) * 2019-12-24 2022-11-22 Miraki Innovation Think Tank Llc COMPOSITION, AND, METHODS FOR TREATMENT OF SUBCUTANEOUS ADIPOSE TISSUE, TO CREATE A TREATMENT PLAN FOR A SUBJECT AND TO GENERATE A COMPOSITION
US20230046673A1 (en) * 2019-12-26 2023-02-16 Miraki Innovation Think Tank Llc Treatment of obstructive sleep apnea
WO2021138252A1 (en) * 2019-12-31 2021-07-08 Miraki Innovative Think Tank Llc Cold solution for inducing therapeutic hypothermia
WO2021151019A1 (en) 2020-01-23 2021-07-29 The General Hospital Corporation Novel method of enhanced drug delivery to the nervous system
EP4126055A4 (en) * 2020-03-27 2024-05-01 Eyecool Therapeutics Inc Methods of alleviating symptoms of ocular surface discomfort using medical ice slurry
WO2022011336A1 (en) 2020-07-10 2022-01-13 C° Change Surgical Llc Injectable slush feed supply
WO2022016015A1 (en) * 2020-07-15 2022-01-20 Lyotip, Inc. Formulations for tetracaine and lidocaine
US20220071900A1 (en) * 2020-09-08 2022-03-10 Brixton Biosciences, Inc. Systems and methods for preparing and transporting an injectable slurry
US20220087250A1 (en) * 2020-09-24 2022-03-24 Everest Medical Innovation GmbH Cryoprotective Compositions and Methods for Protection of a Surgical Site During Cryosurgery
US11241330B1 (en) 2021-04-02 2022-02-08 Brixton Biosciences, Inc. Apparatus for creation of injectable slurry
US11490925B1 (en) 2021-06-09 2022-11-08 Mohammed A. Alsufyani Combination ultrasound transducer and fat injecting cannula
EP4352430A1 (en) * 2021-06-11 2024-04-17 Brixton Biosciences, Inc. Methods of creating a slurry using liposome emulsions
WO2023064528A1 (en) * 2021-10-14 2023-04-20 The General Hospital Corporation Compositions and methods for treatment of obstructive sleep apnea
WO2023150739A2 (en) * 2022-02-07 2023-08-10 Moskovitz Martin J Cryo-surgical device and materials and method of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130190744A1 (en) * 2010-02-15 2013-07-25 The General Hospital Corporation Methods and devices for selective disruption of visceral fat by controlled cooling

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US5143063A (en) 1988-02-09 1992-09-01 Fellner Donald G Method of removing adipose tissue from the body
JP2512095B2 (en) * 1988-08-12 1996-07-03 株式会社日立製作所 Cold heat generation method
JP2792702B2 (en) 1988-10-05 1998-09-03 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド Method for preparing liposomes with improved stability when dried
US5005364A (en) 1990-02-07 1991-04-09 Nelson William R Apparatus for and method of making and delivering slush ice
ES2103376T3 (en) 1991-07-05 1997-09-16 Nycomed Imaging As IMPROVEMENTS INTRODUCED IN CONTRAST AGENTS.
US5507790A (en) 1994-03-21 1996-04-16 Weiss; William V. Method of non-invasive reduction of human site-specific subcutaneous fat tissue deposits by accelerated lipolysis metabolism
US5769879A (en) 1995-06-07 1998-06-23 Medical Contouring Corporation Microwave applicator and method of operation
US6126657A (en) 1996-02-23 2000-10-03 Somnus Medical Technologies, Inc. Apparatus for treatment of air way obstructions
US6464697B1 (en) 1998-02-19 2002-10-15 Curon Medical, Inc. Stomach and adjoining tissue regions in the esophagus
US6467953B1 (en) 1999-03-30 2002-10-22 Medical Solutions, Inc. Method and apparatus for monitoring temperature of intravenously delivered fluids and other medical items
US7892229B2 (en) 2003-01-18 2011-02-22 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US6126684A (en) 1998-04-21 2000-10-03 The Regents Of The University Of California Indwelling heat exchange catheter and method of using same
US6546932B1 (en) 1999-04-05 2003-04-15 Cryocath Technologies Inc. Cryogenic method and apparatus for promoting angiogenesis
JP3111219B1 (en) * 1999-05-25 2000-11-20 工業技術院長 Cold heat transport method and apparatus using polyvinyl alcohol
PT1196144E (en) 1999-07-16 2004-12-31 Alza Corp COMPOSITION OF LIPOSOMES WITH RESISTANCE TO FREEZE / DEFROST DAMAGE
US6596333B1 (en) 1999-07-21 2003-07-22 Nestec S.A. Process for producing aerated frozen products
US6413444B1 (en) 1999-08-02 2002-07-02 The University Of Chicago Methods and apparatus for producing phase change ice particulate saline slurries
US6962601B2 (en) 1999-08-02 2005-11-08 University Of Chicago Office Of Technology Transfer Method for inducing hypothermia
US7422601B2 (en) * 1999-08-02 2008-09-09 University Of Chicago Office Of Technology Transfer Method for inducing hypothermia
US6244052B1 (en) * 1999-08-02 2001-06-12 The University Of Chicago Method and apparatus for producing phase change ice particulate perfluorocarbon slurries
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7306591B2 (en) 2000-10-02 2007-12-11 Novasys Medical, Inc. Apparatus and methods for treating female urinary incontinence
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US7897141B2 (en) 2002-04-01 2011-03-01 Drexel University Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
US20030032996A1 (en) * 2001-08-08 2003-02-13 Hallman Arlan Jay Cryogenic massage tube and compress
US6709431B2 (en) 2001-12-18 2004-03-23 Scimed Life Systems, Inc. Cryo-temperature monitoring
EP1480650B1 (en) * 2002-02-26 2010-04-28 AstraZeneca AB Novel crystalline forms of the anti-cancer compound zd1839
MXPA04008992A (en) 2002-03-15 2005-10-18 Gen Hospital Corp Methods and devices for selective disruption of fatty tissue by controlled cooling.
US8840608B2 (en) 2002-03-15 2014-09-23 The General Hospital Corporation Methods and devices for selective disruption of fatty tissue by controlled cooling
US6858025B2 (en) 2002-08-06 2005-02-22 Medically Advanced Designs, Llc Cryo-surgical apparatus and method of use
US7211104B2 (en) 2002-10-08 2007-05-01 Vital Wear, Inc. Contrast therapy system and method
US7083612B2 (en) 2003-01-15 2006-08-01 Cryodynamics, Llc Cryotherapy system
US20040258760A1 (en) 2003-03-20 2004-12-23 Wheatley Margaret A. Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production
WO2004088233A2 (en) 2003-03-26 2004-10-14 Regents Of The University Of Minnesota Thermal surgical procedures and compositions
US20060161232A1 (en) 2005-01-18 2006-07-20 Kasza, Oras and Son to The University of Chicago Phase-change particulate ice slurry coolant medical delivery tubing and insertion devices
US7713266B2 (en) 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7850683B2 (en) 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
WO2006127897A2 (en) 2005-05-24 2006-11-30 Uab Research Foundation Surgical delivery devices and methods
US7389653B2 (en) * 2005-09-15 2008-06-24 The University Of Chicago Medical ice slurry production device
US20070093697A1 (en) 2005-10-21 2007-04-26 Theranova, Llc Method and apparatus for detection of right to left shunting in the cardiopulmonary vasculature
US7854754B2 (en) 2006-02-22 2010-12-21 Zeltiq Aesthetics, Inc. Cooling device for removing heat from subcutaneous lipid-rich cells
GB0615287D0 (en) 2006-08-01 2006-09-06 Ares Trading Sa Integral membrane protein
US8192474B2 (en) 2006-09-26 2012-06-05 Zeltiq Aesthetics, Inc. Tissue treatment methods
JP2010508130A (en) 2006-10-31 2010-03-18 ゼルティック エステティックス インコーポレイテッド Method and apparatus for cooling subcutaneous high lipid cells or subcutaneous high lipid tissue
US9254162B2 (en) 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US20080247957A1 (en) 2007-02-16 2008-10-09 Drexel University Advanced drug delivery strategy and platform for minimally-invasive treatment of liver cancer
WO2008150871A1 (en) 2007-05-30 2008-12-11 Critical Care Innovations, Inc. Process and device for selectively treating interstitial tissue
US20090028797A1 (en) 2007-06-14 2009-01-29 Drexel University Novel polymeric ultrasound contrast agent and methods of making thereof
US8439960B2 (en) 2007-07-09 2013-05-14 Velomedix, Inc. Hypothermia devices and methods
US8523927B2 (en) 2007-07-13 2013-09-03 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
AU2008309520A1 (en) 2007-10-12 2009-04-16 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Method for opening tight junctions
US8298216B2 (en) 2007-11-14 2012-10-30 Myoscience, Inc. Pain management using cryogenic remodeling
WO2009102367A2 (en) 2007-11-19 2009-08-20 The Regents Of The University Of Colorado Tight junction protein modulators and uses thereof
US20090234325A1 (en) 2008-03-17 2009-09-17 Allan Rozenberg Methods and devices for non-invasive cerebral and systemic cooling
JP2011516168A (en) 2008-04-01 2011-05-26 ザ ジェネラル ホスピタル コーポレイション Method and apparatus for cooling biological tissue
US8505315B2 (en) * 2008-04-15 2013-08-13 Uchicago Argonne, Llc Enhanced integrated operation blender based sterile medical ice slurry production device
US7874167B2 (en) 2008-06-06 2011-01-25 C Change Surgical Llc Method and apparatus for producing slush for surgical use
US20100036295A1 (en) 2008-08-08 2010-02-11 Palomar Medical Technologies, Inc. Method and apparatus for fractional deformation and treatment of cutaneous and subcutaneous tissue
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8414356B2 (en) * 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8603073B2 (en) 2008-12-17 2013-12-10 Zeltiq Aesthetics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
WO2010083281A1 (en) 2009-01-15 2010-07-22 Boston Scientific Scimed, Inc. Controlling depth of cryoablation
US8608696B1 (en) 2009-02-24 2013-12-17 North Carolina State University Rapid fluid cooling devices and methods for cooling fluids
US20110009748A1 (en) 2009-06-11 2011-01-13 Galil Medical Ltd. Transperineal prostate biopsy system and methods
US20130011332A1 (en) 2009-09-15 2013-01-10 Searete Llc, Frozen Compositions and Methods for Piercing a Substrate
US20140200511A1 (en) * 2009-10-30 2014-07-17 Searete Llc Systems, devices, and methods for making or administering frozen particles
EP2608837B1 (en) 2010-08-26 2016-05-04 Cryomedix, LLC Cryoablation balloon catheter
US9095320B2 (en) 2010-09-27 2015-08-04 CyroMedix, LLC Cryo-induced renal neuromodulation devices and methods
US20120136344A1 (en) 2010-10-26 2012-05-31 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US9060754B2 (en) 2010-10-26 2015-06-23 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
BR112013014728A2 (en) 2010-12-13 2016-10-04 Myoscience Inc Hyperdynamic Facial Wrinkle Reduction Method
GB2485864B (en) 2011-07-14 2013-05-29 Ide Technologies Ltd Vacuum ice maker (vim) with an integrated water vapor depostion process
WO2012106260A2 (en) 2011-02-01 2012-08-09 Channel Medsystems, Inc. Methods and apparatus for cyrogenic treatment of a body cavity or lumen
WO2012174161A1 (en) 2011-06-14 2012-12-20 Aerin Medical, Inc. Devices for treating nasal airways
EP2561886A1 (en) 2011-08-23 2013-02-27 Forschungsverbund Berlin e.V. Peptide adjuvant for improved peripheral analgesia
KR20220141906A (en) 2011-10-21 2022-10-20 셀라토 파마슈티칼즈, 인코포레이티드 Lyophilized liposomes
US9974684B2 (en) 2011-11-16 2018-05-22 The General Hospital Corporation Method and apparatus for cryogenic treatment of skin tissue
BR112014017175A8 (en) 2012-01-13 2017-07-04 Myoscience Inc skin protection for subdermal cryogenic remodeling for cosmetic and other treatments
US9398930B2 (en) 2012-06-01 2016-07-26 Cibiem, Inc. Percutaneous methods and devices for carotid body ablation
JP6168644B2 (en) 2012-07-12 2017-07-26 国立大学法人弘前大学 Ice slurry manufacturing apparatus and ice slurry manufacturing method
US9844460B2 (en) 2013-03-14 2017-12-19 Zeltiq Aesthetics, Inc. Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same
US9023022B2 (en) 2013-03-15 2015-05-05 Warsaw Orthopedic, Inc. Nerve and soft tissue ablation device having release instrument
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
US9033966B2 (en) 2013-03-15 2015-05-19 Warsaw Orthopedic, Inc. Nerve and soft tissue ablation device
US9023023B2 (en) 2013-03-15 2015-05-05 Warsaw Orthopedic, Inc. Nerve and soft tissue ablation device
US9131975B2 (en) 2013-03-15 2015-09-15 Warsaw Orthopedic, Inc. Nerve and soft tissue ablation device
EP2967706B1 (en) 2013-03-15 2021-09-08 Pacira CryoTech, Inc. Cryogenic blunt dissection devices
CN105792875B (en) 2013-08-05 2019-05-31 吴粤 The method and instrument of one preparation and conveying for the medical ice slurry of bubble-free of cryotherapy
US9687288B2 (en) 2013-09-30 2017-06-27 Arrinex, Inc. Apparatus and methods for treating rhinitis
US10660688B2 (en) 2014-05-12 2020-05-26 Gary Kalser Cryotherapy device with cryoprotection and methods for performing cryotherapy with cryoprotection
US9763743B2 (en) 2014-07-25 2017-09-19 Arrinex, Inc. Apparatus and method for treating rhinitis
US10646666B2 (en) 2014-08-27 2020-05-12 Tva Medical, Inc. Cryolipolysis devices and methods therefor
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
WO2016033380A1 (en) 2014-08-28 2016-03-03 The General Hospital Corporation Compositions and methods for treatment of neurological disorders
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US9549843B2 (en) 2014-11-30 2017-01-24 C° Change Surgical Llc Production of well-mixed surgical slush
CN204468406U (en) 2015-02-05 2015-07-15 张淑华 A kind of novel portable cold compress device
US10470813B2 (en) 2015-03-12 2019-11-12 Pacira Cryotech, Inc. Methods and systems for preventing neuroma formations
US20160317346A1 (en) 2015-04-28 2016-11-03 Zeltiq Aesthetics, Inc. Systems and methods for monitoring cooling of skin and tissue to identify freeze events
AU2017206118B2 (en) 2016-01-07 2021-09-30 Zeltiq Aesthetics, Inc. Temperature-dependent adhesion between applicator and skin during cooling of tissue
CN114576893A (en) 2016-02-26 2022-06-03 通用医疗公司 Medical ice slurry production and delivery system and method
CN105640642B (en) 2016-04-07 2018-01-12 上海导向医疗系统有限公司 Interior cooled microwave ablation needle with dilating sacculus
US11382790B2 (en) 2016-05-10 2022-07-12 Zeltiq Aesthetics, Inc. Skin freezing systems for treating acne and skin conditions
DE102016115387B3 (en) 2016-08-18 2018-02-01 Cardiolectra GmbH Medical device for denervation of renal perivascular nerves
WO2018044825A1 (en) 2016-08-30 2018-03-08 The General Hospital Corporation Cryotherapy and cryoablation systems and methods for treatment of tissue
KR20200020657A (en) 2016-11-02 2020-02-26 크리스토퍼 제이 피 벨리스 Devices and Methods for Slurry Generation
KR101905830B1 (en) 2016-11-15 2018-10-08 울산과학기술원 Cryoanesthesia device, method for controlling cryoanesthesia device and temperature controller of coolant in cryoanesthesia device
US11324673B2 (en) 2016-11-18 2022-05-10 Miraki Innovation Think Tank Llc Cosmetic appearance of skin
ES2936210T3 (en) 2017-02-04 2023-03-15 Vessi Medical Ltd Cryotherapy Device Flow Control
US9980076B1 (en) 2017-02-21 2018-05-22 At&T Intellectual Property I, L.P. Audio adjustment and profile system
CA3065606A1 (en) 2017-03-01 2018-09-07 Miraki Innovation Think Tank Llc Cryotherapies
WO2018175111A1 (en) 2017-03-21 2018-09-27 Zeltiq Aesthetics, Inc. Use of saccharides for cryoprotection and related technology
BR112019020969A8 (en) 2017-04-05 2022-11-16 Miraki Innovation Think Tank Llc COLD FLUID PASTE CONTAINMENT
US11439532B2 (en) 2017-04-05 2022-09-13 Miraki Innovation Think Tank Llc Point of delivery cold slurry generation
US10500342B2 (en) 2017-08-21 2019-12-10 Miraki Innovation Think Tank Llc Cold slurry syringe
US11523855B2 (en) 2018-09-28 2022-12-13 Team Neuro LLC Spinal pain management system and method
JP2022513342A (en) 2018-10-04 2022-02-07 ミラキ イノベーション シンク タンク エルエルシー Slurry and solution composition
KR20210073541A (en) 2018-10-04 2021-06-18 미라키 이노베이션 씽크 탱크 엘엘씨 How to treat the subcutaneous fat layer
WO2020077090A1 (en) 2018-10-10 2020-04-16 Miraki Innovation Think Tank Llc Systems and methods of generating slurry for injection
WO2020077089A1 (en) 2018-10-10 2020-04-16 Miraki Innovation Think Tank Llc Systems and methods for generating slurry
SG11202103636TA (en) 2018-10-12 2021-05-28 Miraki Innovation Think Tank Llc Cold solution for fat reduction
US20220273569A1 (en) 2019-07-24 2022-09-01 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
US20210038277A1 (en) 2019-08-07 2021-02-11 Christopher M. Shaari Systems and methods for cryogenic treatment of headache
EP4031042A1 (en) 2019-09-17 2022-07-27 Arrinex, Inc. Apparatus and methods for improved nasal cavity treatments
BR112022012482A2 (en) 2019-12-24 2022-11-22 Miraki Innovation Think Tank Llc COMPOSITION, AND, METHODS FOR TREATMENT OF SUBCUTANEOUS ADIPOSE TISSUE, TO CREATE A TREATMENT PLAN FOR A SUBJECT AND TO GENERATE A COMPOSITION
US20230046673A1 (en) 2019-12-26 2023-02-16 Miraki Innovation Think Tank Llc Treatment of obstructive sleep apnea
WO2021151019A1 (en) 2020-01-23 2021-07-29 The General Hospital Corporation Novel method of enhanced drug delivery to the nervous system
US20230069123A1 (en) 2020-02-19 2023-03-02 Cryosa, Inc. Systems and methods for treatment of obstructive sleep apnea
EP4126055A4 (en) 2020-03-27 2024-05-01 Eyecool Therapeutics Inc Methods of alleviating symptoms of ocular surface discomfort using medical ice slurry
US20210330927A1 (en) 2020-04-27 2021-10-28 Black Cat Medical Llc Method of performing cryoneurolysis
US20220071900A1 (en) 2020-09-08 2022-03-10 Brixton Biosciences, Inc. Systems and methods for preparing and transporting an injectable slurry
US20220211923A1 (en) 2020-09-24 2022-07-07 Everest Medical Innovation GmbH Cryoprotective Compositions, Surgical Kits, and Methods for Protection of a Surgical Site During Cryosurgery
US20220087250A1 (en) 2020-09-24 2022-03-24 Everest Medical Innovation GmbH Cryoprotective Compositions and Methods for Protection of a Surgical Site During Cryosurgery
US20220409428A1 (en) 2021-06-23 2022-12-29 Black Cat Medical Llc Method of performing cryoneurolysis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130190744A1 (en) * 2010-02-15 2013-07-25 The General Hospital Corporation Methods and devices for selective disruption of visceral fat by controlled cooling

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CONAWAY B: "Icepacks in diabeticneuropathy", THE PHYSICAL THERAPY REVIEW, OXFORD UNIVERSITY PRESS, US, vol. 41, no. 8, 1 August 1961 (1961-08-01), pages 586 - 588, XP009503866, ISSN: 0735-7435, DOI: 10.1093/PTJ/41.8.586 *

Also Published As

Publication number Publication date
PL3185854T3 (en) 2022-01-31
BR112017003111A2 (en) 2017-12-05
CA2958768C (en) 2023-08-29
MX2017002274A (en) 2017-05-22
AU2023214304A1 (en) 2023-08-31
EP3185854B1 (en) 2021-10-06
CN106794138B (en) 2021-10-01
EP3185876B1 (en) 2022-08-10
BR112017003143B1 (en) 2023-12-05
EP3185876A1 (en) 2017-07-05
AU2021200481B2 (en) 2023-05-11
US11938188B2 (en) 2024-03-26
ES2898097T3 (en) 2022-03-03
CN107106481A (en) 2017-08-29
JP6707525B2 (en) 2020-06-10
EP3185854A1 (en) 2017-07-05
CN106794138A (en) 2017-05-31
JP7240447B2 (en) 2023-03-15
MX2021007621A (en) 2021-08-11
SG11201701505RA (en) 2017-03-30
JP2017526684A (en) 2017-09-14
ZA201701080B (en) 2019-05-29
JP2023060133A (en) 2023-04-27
JP6903792B2 (en) 2021-07-14
SG10201913572TA (en) 2020-03-30
AU2015308790B2 (en) 2020-12-03
WO2016033380A1 (en) 2016-03-03
AU2015308790A1 (en) 2017-03-02
US20170274078A1 (en) 2017-09-28
DK3185876T3 (en) 2022-10-31
CA2958769A1 (en) 2016-03-03
WO2016033384A1 (en) 2016-03-03
JP7201727B2 (en) 2023-01-10
JP2020143113A (en) 2020-09-10
PT3185854T (en) 2021-12-03
EP4176885A1 (en) 2023-05-10
SG11201701504WA (en) 2017-03-30
SG10201913564WA (en) 2020-03-30
JP2017529336A (en) 2017-10-05
BR112017003143A2 (en) 2017-11-28
KR20170044199A (en) 2017-04-24
US20240042034A1 (en) 2024-02-08
JP2021152055A (en) 2021-09-30
KR102507789B1 (en) 2023-03-07
KR20170045330A (en) 2017-04-26
JP6858698B2 (en) 2021-04-21
US11964017B2 (en) 2024-04-23
AU2015308794A1 (en) 2017-03-02
US20170274011A1 (en) 2017-09-28
BR112017003111B1 (en) 2021-10-13
DK3185854T3 (en) 2021-12-20
ZA201701048B (en) 2023-12-20
US20210236639A1 (en) 2021-08-05
US20210244817A1 (en) 2021-08-12
US11826427B2 (en) 2023-11-28
CA2958768A1 (en) 2016-03-03
MX2017002271A (en) 2017-05-22
CN117064838A (en) 2023-11-17
ZA201901279B (en) 2021-08-25
EP3988105A1 (en) 2022-04-27
CN113813222A (en) 2021-12-21
AU2021200481A1 (en) 2021-02-25
EP3185854A4 (en) 2018-07-25
JP2021098748A (en) 2021-07-01

Similar Documents

Publication Publication Date Title
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
EP3675882A4 (en) Methods and compositions for treatment of microbiome-associated disorders
IL304429A (en) Methods and compositions for treatment of epileptic disorders
EP3349760A4 (en) Compositions and methods for treating neurological disorders
EP3389725A4 (en) Compositions and methods for treatment of central nervous system diseases
EP3340982A4 (en) Compounds for treatment of immune and inflammatory disorders
EP3212226A4 (en) Compositions and methods of use for treating metabolic disorders
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
EP3174894A4 (en) Compositions and methods of use for treating metabolic disorders
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
EP3182977A4 (en) Compositions and methods to treat vision disorders
EP3209320A4 (en) Methods of using interleukin-10 for treating diseases and disorders
EP3189036A4 (en) Compositions and methods for treating proliferation disorders
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
EP3131556A4 (en) Methods and compositions for treatment of copd diseases
EP3240577A4 (en) Methods and compositions for treating brain diseases
EP3481958A4 (en) Methods and compositions for treatment of disorders and diseases involving rdh12
EP3194027A4 (en) Methods and compositions for treating psychotic disorders
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders
EP3200828A4 (en) Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
EP3142674A4 (en) Methods and compositions for treatment of macrophage-related disorders
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
EP3393460A4 (en) Compositions and methods of treatment for mvid and related diseases
GB201612043D0 (en) Composition for treatment of disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170328

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GARIBYAN, LILIT

Inventor name: FARINELLI, WILLIAM, A.

Inventor name: JAVORSKY, EMILIA

Inventor name: ANDERSON, RICHARD, ROX

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180319

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 33/00 20060101AFI20180313BHEP

Ipc: A61K 31/045 20060101ALI20180313BHEP

Ipc: A61K 47/02 20060101ALI20180313BHEP

Ipc: A61K 31/047 20060101ALI20180313BHEP

Ipc: A61K 31/718 20060101ALI20180313BHEP

Ipc: A61K 47/26 20060101ALI20180313BHEP

Ipc: A61K 9/00 20060101ALI20180313BHEP

Ipc: A61K 31/137 20060101ALI20180313BHEP

Ipc: A61K 31/7004 20060101ALI20180313BHEP

Ipc: A61K 31/765 20060101ALI20180313BHEP

Ipc: A61K 45/06 20060101ALI20180313BHEP

Ipc: A61K 47/10 20170101ALI20180313BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200421

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015080299

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0035300000

Ipc: A61K0031045000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20220201BHEP

Ipc: A61P 37/08 20060101ALI20220201BHEP

Ipc: A61P 35/00 20060101ALI20220201BHEP

Ipc: A61P 25/00 20060101ALI20220201BHEP

Ipc: A61P 23/02 20060101ALI20220201BHEP

Ipc: A61P 19/02 20060101ALI20220201BHEP

Ipc: A61P 17/00 20060101ALI20220201BHEP

Ipc: A61P 13/02 20060101ALI20220201BHEP

Ipc: A61K 47/26 20060101ALI20220201BHEP

Ipc: A61K 47/10 20170101ALI20220201BHEP

Ipc: A61K 47/02 20060101ALI20220201BHEP

Ipc: A61K 33/00 20060101ALI20220201BHEP

Ipc: A61K 31/445 20060101ALI20220201BHEP

Ipc: A61K 31/765 20060101ALI20220201BHEP

Ipc: A61K 31/245 20060101ALI20220201BHEP

Ipc: A61K 31/718 20060101ALI20220201BHEP

Ipc: A61K 31/7004 20060101ALI20220201BHEP

Ipc: A61K 31/137 20060101ALI20220201BHEP

Ipc: A61K 31/047 20060101ALI20220201BHEP

Ipc: A61K 31/045 20060101AFI20220201BHEP

INTG Intention to grant announced

Effective date: 20220222

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1509982

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220815

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015080299

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20221027

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221212

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221110

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1509982

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221210

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221111

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220827

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015080299

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

26N No opposition filed

Effective date: 20230511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230826

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230822

Year of fee payment: 9

Ref country code: IE

Payment date: 20230828

Year of fee payment: 9

Ref country code: GB

Payment date: 20230828

Year of fee payment: 9

Ref country code: FI

Payment date: 20230825

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230827

Year of fee payment: 9

Ref country code: FR

Payment date: 20230825

Year of fee payment: 9

Ref country code: DK

Payment date: 20230829

Year of fee payment: 9

Ref country code: DE

Payment date: 20230829

Year of fee payment: 9

Ref country code: BE

Payment date: 20230828

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20150827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810